SalaryGuide
AboutPricingFor Employers

Marketing jobs

4 marketing jobs

Summit Therapeutics logo
4 weeks ago

Director, Patient Marketing

Summit Therapeutics

Princeton, NJ (On-site)Full time$203K/yr – $254K/yr
Summit Therapeutics logo
4 weeks ago

Director, Marketing Operations

Summit Therapeutics

Princeton, NJ (On-site)Full time$190K/yr – $240K/yr
Summit Therapeutics logo
2 months ago

Vice President, US Marketing

Summit Therapeutics

Princeton, NJ (On-site)Full time$315K/yr – $350K/yr
Summit Therapeutics logo
4 months ago

Associate Director, HCP Promotional Marketing

Summit Therapeutics

Princeton, NJ (On-site)Full time$174K/yr – $205K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Summit Therapeutics logo

Director, Patient Marketing

Summit Therapeutics

Princeton, NJ (On-site)

$203K/yr - $254K/yrIn-houseFull-timeDirector/executive10+ years exp.
4 weeks ago
Summit Therapeutics logo

Director, Marketing Operations

Summit Therapeutics

Princeton, NJ (On-site)

$190K/yr - $240K/yrIn-houseFull-timeDirector/executive10+ years exp.
4 weeks ago
Summit Therapeutics logo

Vice President, US Marketing

Summit Therapeutics

Princeton, NJ (On-site)

$315K/yr - $350K/yrIn-houseFull-timeSenior level15+ years exp.
2 months ago
Summit Therapeutics logo

Associate Director, HCP Promotional Marketing

Summit Therapeutics

Princeton, NJ (On-site)

$174K/yr - $205K/yrIn-houseFull-timeSenior level8+ years exp.
4 months ago
Summit Therapeutics logo
Summit Therapeutics

Director, Patient Marketing

Princeton, NJ (On-site)

$203K/yr – $254K/yrDirector/Executive10+ years expFull time

Posted 4 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and lead the patient marketing strategy for oncology launches, focusing on NSCLC, with cross-functional alignment and a data-driven activation plan that translates clinical insight into patient education and demand.

  • Own the patient strategy, messaging, and value proposition informed by market research to educate and activate patients.
  • Lead cross-functional collaboration to deliver cohesive patient digital marketing and ensure stakeholder alignment.
  • Manage the Patient AOR relationship and steer high impact creative, media, and digital execution.

Job Description

Responsibilities

  • Lead the development and execution of patient promotional strategies and tactics to support current and future oncology launches, with an initial focus on NSCLC
  • Develop patient strategy, messaging, and value proposition grounded in market research, and translate insights into disease and treatment awareness initiatives that drive education, urgency, and patient activation
  • Partner cross-functionally with HCP Marketing, Patient Advocacy, and Omnichannel Marketing to ensure cohesive brand strategy, alignment with patient community needs, and execution of an effective patient digital marketing approach
  • Own the Patient Agency of Record (AOR) relationship, setting strategic direction and ensuring high-quality execution across creative, media, and digital initiatives
  • Establish KPIs and performance metrics to measure campaign effectiveness, inform optimization, and guide ongoing patient channel strategy
  • Manage patient promotional budgets to ensure efficient allocation of resources and maximize impact
  • Travel as needed to support business priorities and engage with key stakeholders
  • All other duties as assigned.

Requirements

  • Bachelor2s degree in Business, Marketing, or a related field; MBA or advanced degree preferred
  • Minimum of 10+ years of pharmaceutical or biotech commercial experience, including significant leadership in oncology patient marketing
  • Demonstrated experience leading the patient aspect of 1-2 major US commercial launches, preferably in oncology
  • Deep understanding of direct-to-consumer (DTC) strategy and patient activation in complex & competitive therapeutic areas
  • Direct experience managing and influencing Agency of Record (AOR) relationships across creative, media, digital, and PR
  • Proven ability to translate complex clinical data into clear, compelling, and compliant patient-facing messaging
  • Excellent strategic thinking, communication, and leadership skills
  • Proven ability to partner and lead cross-functional collaboration across Marketing, Insights, Market Access, Medical, Legal, and Compliance
  • Demonstrated record of operating successfully within regulatory, legal, and operational requirements
  • Ability to thrive in fast-paced, pre-launch or launch-phase environments with evolving data and priorities
  • Willingness to travel as business needs require

Preferred

  • MBA or advanced degree preferred
Summit Therapeutics logo

Summit Therapeutics

Summit Mission Statement:To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate.We accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position. Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK.

Founded in 2003
Miami, Florida, USA
321 employees
www.smmttx.com

Traffic Signals

Monthly Visitors
34.1K
Traffic Source Mix
Search
50.3%
Direct
40.7%
Referral
6.3%
Social
1.6%
Paid
1.1%

Headcount Trend

Current headcount: ~325

Marketing Team

Marketing Roles Posted (Last 30 Days)
2

Funding

Total Funding
$1.8B
Last Raise
$500M
Post IPO Equity, 5 months ago

Funding History

  • Oct 2025
    Post IPO Equity • $500M
  • Sep 2024
    Post IPO Equity • $235M
  • Jun 2024
    Post IPO Equity • $200M

Recent News

Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development
Dec 11, 2025 • Yahoo Finance
Don't Buy Summit Therapeutics Until This Big Thing Happen
Dec 3, 2025 • Nasdaq
Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases
Dec 2, 2025 • Yahoo Finance
January 2026 Options Now Available For Summit Therapeutics (SMMT)
Nov 26, 2025 • Nasdaq
Summit Therapeutics Inc Reports Positive Phase III Trial Results
Nov 7, 2025 • TradingView — Track All Markets
Summit Therapeutics to Present at Upcoming Investor Conferences
Nov 4, 2025 • Business Wire
Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed?
Nov 3, 2025 • Yahoo Finance
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025
Oct 30, 2025 • Yahoo Finance
Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares
Oct 28, 2025 • Yahoo Finance
Thursday’s Insider Moves: Summit Therapeutics’ Directors Lead Buying Spree
Oct 24, 2025 • Investing.com
Summit Therapeutics: A Risky Bet in the Biotech Arena?
Oct 24, 2025 • The Motley Fool
Summit Therapeutics Raises $500 Million in Private Placement
Oct 22, 2025 • Business Wire
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab
Oct 21, 2025 • Yahoo Finance
Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ...
Oct 20, 2025 • Yahoo Finance
Summit Therapeutics Posts Wider Loss In Q3
Oct 20, 2025 • Nasdaq
What's Going On With Summit Therapeutics Stock On Monday? - Summit Therapeutics (NASDAQ:SMMT)
Oct 20, 2025 • Benzinga
Summit Therapeutics Inc. SEC 10-Q Report
Oct 20, 2025 • TradingView — Track All Markets
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
Oct 20, 2025 • Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Oct 18, 2025 • PR Newswire
Summit Therapeutics (SMMT): A Valuation Perspective After Recent 16% Share Price Climb
Oct 18, 2025 • Yahoo Finance
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
Oct 17, 2025 • Business Wire
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Oct 15, 2025 • Yahoo Finance
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Oct 15, 2025 • Business Wire
Where is Summit Therapeutics (SMMT) Headed According to Analysts?
Oct 7, 2025 • Yahoo Finance
A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation
Oct 2, 2025 • Yahoo Finance
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025
Oct 1, 2025 • Yahoo Finance
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 24, 2025 • Business Wire
Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China
Sep 18, 2025 • Yahoo Finance
Barclays Initiates Coverage of Summit Therapeutics (SMMT) with Underweight Recommendation
Sep 17, 2025 • Nasdaq
Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
Sep 16, 2025 • GlobeNewswire
Summit Therapeutics stock gains on insider buys (SMMT:NASDAQ)
Sep 12, 2025 • Seeking Alpha
Summit Therapeutics Stock (SMMT) Opinions on HARMONi Trial Data Release | SMMT Stock News
Sep 12, 2025 • Quiver Quantitative
Duggan buys Summit Therapeutics (SMMT) shares worth $5.9m
Sep 11, 2025 • Investing.com
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
Sep 10, 2025 • GlobeNewswire
Summit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval Questions
Sep 10, 2025 • Yahoo Finance
Summit’s Stock Plunge: What Lies Ahead?
Sep 10, 2025 • StocksToTrade
Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating
Sep 10, 2025 • Insider Monkey
Is Summit Therapeutics a Buy, Sell, or Hold Now?
Sep 9, 2025 • Nasdaq
Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating
Sep 9, 2025 • Yahoo Finance
Summit Therapeutics Enters Oversold Territory (SMMT)
Sep 8, 2025 • Nasdaq
Summit's High-Profile Drug Flops And Shares Crash
Sep 8, 2025 • Investor's Business Daily
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Sep 8, 2025 • Yahoo Finance
Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend
Sep 7, 2025 • Fierce Pharma
Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster
Sep 7, 2025 • statnews.com
Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3
Sep 4, 2025 • Stocktwits
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
Sep 3, 2025 • Business Wire
H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44
Aug 30, 2025 • Yahoo Finance
Summit Therapeutics stock price target raised to $50 from $44 at H.C. Wainwright
Aug 27, 2025 • Investing.com
Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism
Aug 18, 2025 • Yahoo Finance
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call
Aug 13, 2025 • Yahoo Finance
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11, 2025 • Yahoo Finance
Summit Therapeutics Inc. SEC 10-Q Report
Aug 11, 2025 • TradingView
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11, 2025 • Business Wire
Summit Therapeutics Insiders Added US$78.0m Of Stock To Their Holdings
Aug 2, 2025 • Yahoo Finance
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings
Jul 17, 2025 • Yahoo Finance
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors (SMMT)
Jul 17, 2025 • Seeking Alpha
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
Jul 14, 2025 • Business Wire
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal
Jul 10, 2025 • Yahoo Finance
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal
Jul 10, 2025 • Insider Monkey
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal
Jul 9, 2025 • Yahoo Finance
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Jul 7, 2025 • Yahoo Finance
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Jul 6, 2025 • Yahoo Finance
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Jul 4, 2025 • Seeking Alpha
Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
Jul 3, 2025 • Reuters
Summit Is in Talks for $15 Billion Partnership With AstraZeneca
Jul 3, 2025 • Bloomberg.com
Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks
Jul 3, 2025 • Investopedia
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Jul 2, 2025 • Nasdaq
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
Jul 1, 2025 • Yahoo Finance
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Jun 30, 2025 • Yahoo Finance
Revolution Medicines and Summit Therapeutics Enter into
Jun 30, 2025 • GlobeNewswire
H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
Jun 25, 2025 • Yahoo Finance
Why Summit Therapeutics Stock Tanked Today
Jun 11, 2025 • Nasdaq
Why Summit Therapeutics Stock Tanked Today
Jun 11, 2025 • Yahoo Finance
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm
Jun 6, 2025 • GlobeNewswire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 6, 2025 • Business Wire
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
Jun 5, 2025 • Yahoo Finance
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday
Jun 4, 2025 • Yahoo Finance
Summit Therapeutics: What's This Ivonescimab Rollercoaster
Jun 3, 2025 • Nasdaq
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
Jun 3, 2025 • Yahoo Finance
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Jun 2, 2025 • Yahoo Finance
Summit Therapeutics: Market Overreaction Creates Opportunity (NASDAQ:SMMT)
Jun 2, 2025 • Seeking Alpha
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Jun 2, 2025 • Nasdaq
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.
May 30, 2025 • Barron's
Summit Therapeutics stock dips after clinical trial results
May 30, 2025 • Investing.com
Why Summit Therapeutics Plunged Today
May 30, 2025 • Nasdaq
Why Summit Therapeutics Plunged Today
May 30, 2025 • The Motley Fool
Summit shrugs off survival miss with its VEGF bispecific
May 30, 2025 • pharmaphorum
Summit Therapeutics: Critical NSCLC Study Readout Jeopardizes Ivonesimab Approval (SMMT)
May 30, 2025 • Seeking Alpha
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?
May 26, 2025 • Yahoo Finance
Summit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025
May 22, 2025 • Yahoo Finance
What to know about Summit Therapeutics’ looming clinical trial readout
May 15, 2025 • statnews.com
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain
May 9, 2025 • Yahoo Finance
Can Summit Therapeutics Stock Double Your Money?
May 7, 2025 • Nasdaq
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
May 6, 2025 • Yahoo Finance
Why Summit Therapeutics Inc. (SMMT) Soared Last Week
May 4, 2025 • Yahoo Finance
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
May 1, 2025 • BioSpace
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
May 1, 2025 • Business Wire
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Apr 28, 2025 • Benzinga
Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT)
Apr 26, 2025 • Seeking Alpha
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Apr 25, 2025 • Yahoo Finance